Epigenetic clocks and biological aging in neurodegeneration¶

Analysis ID: SDA-2026-04-01-gap-v2-bc5f270e

Research Question: What are the mechanisms underlying epigenetic clocks and biological aging in neurodegeneration?

Domain: neurodegeneration | Date: 2026-04-01 | Hypotheses: 6 | Target Genes: 6

Debate Quality Score: 0.50/1.00

This notebook presents a comprehensive analysis including:

1. Hypothesis scoring and ranking
2. Gene expression differential analysis
3. Pathway enrichment analysis
4. Statistical tests
5. Debate transcript highlights

1. Hypothesis Ranking¶

The multi-agent debate generated 6 hypotheses, each scored across 10 dimensions. Target genes: KDM6A, TET2, SIRT6, FOXO3, HDAC3, DNMT1.

2. Score Comparison¶

3. Multi-Dimensional Score Radar¶

Radar plot comparing top hypotheses across all 10 scoring dimensions.

4. Differential Gene Expression Analysis¶

Simulated differential expression analysis for 6 target genes comparing control vs disease conditions. Includes volcano plot and expression comparison.

Note: Expression data is simulated based on literature-reported fold changes for demonstration. Replace with real RNA-seq data for production analysis.

5. Pathway Enrichment Analysis¶

Enrichment analysis identifies biological pathways overrepresented among the target genes.

6. Statistical Analysis¶

Comprehensive statistical testing of hypothesis scores including summary statistics, correlation analysis, normality tests, and top-vs-bottom comparison.

7. Debate Highlights¶

Theorist¶

Novel Therapeutic Hypotheses: Epigenetic Clocks and Neurodegeneration¶

Hypothesis 1: TET2-Mediated Demethylation Rejuvenation Therapy¶

Description: Targeted overexpression of TET2 methylcytosine dioxygenase in specific brain regions can reverse pathological DNA methylation patterns associated with accelerated epigenetic aging in neurodegeneration. This approach would restore youthful methylation landscapes at key neuronal survival genes by promoting active demethylation of aberrantly hypermethylated CpG sites.

Target: TET2 (Ten-eleven translocation methylcytosine dioxygenase 2)

*...

Skeptic¶

Critical Evaluation of Epigenetic Clock and Neurodegeneration Hypotheses¶

Hypothesis 1: TET2-Mediated Demethylation Rejuvenation Therapy¶

Specific Weaknesses:¶

1. Lack of specificity: TET2 overexpression would cause global demethylation, not targeted demethylation of pathological sites
2. Developmental disruption: TET2 is crucial for normal development; overexpression could disrupt essential methylation patterns
3. Limited brain penetrance: No evidence provided for effective TET2 overexpression delivery methods to brain tissue

Counter-Evidence:¶

• TET2 overexpression in...

Domain Expert¶

Druggability Assessment: Epigenetic Clock Neurodegeneration Targets¶

Overall Assessment Summary¶

Most hypotheses have fundamental flaws, but I'll assess the top 2-3 for practical drug development feasibility.

Hypothesis 2: HDAC3-Selective Inhibition (Revised Confidence: 0.45)¶

Druggability: MODERATE¶

Target Class: Zinc metalloenzyme - well-established druggable class Chemical Matter Status: Advanced but limited selectivity

Existing Compounds & Clinical Candidates:¶

• RGFP966 (Repligen): Most selective HDAC3 inhibitor, ~40-fold selectivity over other HDACs
• ...

Synthesizer¶

{
  "ranked_hypotheses": [
    {
      "title": "HDAC3-Selective Inhibition for Clock Reset",
      "description": "Selective pharmacological inhibition of HDAC3 can reset accelerated epigenetic clocks by restoring histone acetylation patterns at circadian and metabolic regulatory genes.",
      "target_gene": "HDAC3",
      "dimension_scores": {
        "mechanistic_plausibility": 0.7,
        "evidence_strength": 0.6,
        "novelty": 0.8,
        "feasibility": 0.6,
        "therapeutic_potential": 0.5,
        "druggability": 0.8,
        "safety_profile": 0.4,
        "competiti...

8. Key Citations¶

This analysis cited 36 PubMed papers:

• PMID: 18568025 - https://pubmed.ncbi.nlm.nih.gov/18568025/
• PMID: 20395464 - https://pubmed.ncbi.nlm.nih.gov/20395464/
• PMID: 20644199 - https://pubmed.ncbi.nlm.nih.gov/20644199/
• PMID: 21102463 - https://pubmed.ncbi.nlm.nih.gov/21102463/
• PMID: 21885626 - https://pubmed.ncbi.nlm.nih.gov/21885626/
• PMID: 23086993 - https://pubmed.ncbi.nlm.nih.gov/23086993/
• PMID: 23177740 - https://pubmed.ncbi.nlm.nih.gov/23177740/
• PMID: 24652652 - https://pubmed.ncbi.nlm.nih.gov/24652652/
• PMID: 25219498 - https://pubmed.ncbi.nlm.nih.gov/25219498/
• PMID: 25437561 - https://pubmed.ncbi.nlm.nih.gov/25437561/
• PMID: 26686024 - https://pubmed.ncbi.nlm.nih.gov/26686024/
• PMID: 26694615 - https://pubmed.ncbi.nlm.nih.gov/26694615/
• PMID: 28068668 - https://pubmed.ncbi.nlm.nih.gov/28068668/
• PMID: 28319113 - https://pubmed.ncbi.nlm.nih.gov/28319113/
• PMID: 28329682 - https://pubmed.ncbi.nlm.nih.gov/28329682/
• PMID: 28814570 - https://pubmed.ncbi.nlm.nih.gov/28814570/
• PMID: 29887377 - https://pubmed.ncbi.nlm.nih.gov/29887377/
• PMID: 30135423 - https://pubmed.ncbi.nlm.nih.gov/30135423/
• PMID: 30193097 - https://pubmed.ncbi.nlm.nih.gov/30193097/
• PMID: 30683808 - https://pubmed.ncbi.nlm.nih.gov/30683808/
• PMID: 31167141 - https://pubmed.ncbi.nlm.nih.gov/31167141/
• PMID: 31292147 - https://pubmed.ncbi.nlm.nih.gov/31292147/
• PMID: 31375623 - https://pubmed.ncbi.nlm.nih.gov/31375623/
• PMID: 31748738 - https://pubmed.ncbi.nlm.nih.gov/31748738/
• PMID: 31831667 - https://pubmed.ncbi.nlm.nih.gov/31831667/

Generated: 2026-04-02 10:40 | Platform: SciDEX | Layer: Atlas + Agora

This notebook is a reproducible artifact of multi-agent scientific debate with quantitative analysis.